Journal Mobile Options
Table of Contents
Vol. 62, No. 3, 2013
Issue release date: May 2013

A Weight Loss Diet Intervention Has a Similar Beneficial Effect on Both Metabolically Abnormal Obese and Metabolically Healthy but Obese Premenopausal Women

Ruiz J.R. · Ortega F.B. · Labayen I.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: We studied the effect of a 12-week energy-restricted diet intervention on cardiometabolic risk in two groups of nonmorbid obese premenopausal Caucasian women, i.e. a metabolically abnormal obese (MAO) and a metabolically healthy but obese (MHO) group. Methods: The participants were 53 MAO and 25 MHO women (age range 19-49 years; body mass index inclusion criterion: 30-39.9). We assessed changes in body weight and composition, blood lipids, insulin resistance, hepatic enzymes, inflammatory markers and adipocytokines. Results: Overall, many of the study outcomes improved with the intervention in both MAO and MHO participants, but there was no difference in the magnitude of change between the groups. Body weight, waist circumference and total fat mass decreased significantly in response to the intervention in both MAO and MHO women (all p < 0.001). Fasting insulin, insulin resistance (homeostasis model assessment), hepatic enzymes (alanine aminotransferase and γ-glutamyltransferase), fatty liver index and leptin levels also decreased in both groups after the intervention (all p < 0.001), whereas total cholesterol, triglycerides and C-reactive protein decreased significantly only in MAO women (all p < 0.001). Conclusion: These findings reinforce the idea that MHO women would also benefit from a lifestyle weight reduction intervention.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Karelis AD: Metabolically healthy but obese individuals. Lancet 2008;372:1281-1283.
  2. Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, Sladek R, Rabasa-Lhoret R: Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011;35:971-981.
  3. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB: Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006;91:2906-2912.
  4. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, Mannino S, Crosignani P, Bosi E, Luzi L, Ruotolo G, Perseghin G: Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care 2011;34:210-215.
  5. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M: Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007;30:318-324.
  6. McLaughlin T, Abbasi F, Lamendola C, Reaven G: Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 2007;167:642-648.
  7. St-Pierre AC, Cantin B, Mauriege P, Bergeron J, Dagenais GR, Despres JP, Lamarche B: Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ 2005;172:1301-1305.

    External Resources

  8. Voulgari C, Tentolouris N, Dilaveris P, Tousoulis D, Katsilambros N, Stefanadis C: Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J Am Coll Cardiol 2011;58:1343-1350.
  9. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud'homme D, Rabasa-Lhoret R: The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005;90:4145-4150.
  10. Sesti G, Succurro E, Arturi F, Andreozzi F, Laino I, Perticone M, Sciacqua A, Hribal ML, Perticone F: IGF-1 levels link estimated glomerular filtration rate to insulin resistance in obesity: a study in obese, but metabolically healthy, subjects and obese, insulin-resistant subjects. Nutr Metab Cardiovasc Dis 2011;21:933-940.
  11. Robillard ME, Bellefeuille P, Comtois AS, Aubertin-Leheudre M, Karelis AD: The metabolically healthy but obese postmenopausal woman presents a favourable heart rate variability profile. Scand Cardiovasc J 2011;45:316-320.
  12. Ärnlöv J, Ingelsson E, Sundström J, Lind L: Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010;121:230-236.
  13. Kuk JL, Ardern CI: Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care 2009;32:2297-2299.
  14. Perseghin G: Is a nutritional therapeutic approach unsuitable for metabolically healthy but obese women? Diabetologia 2008;51:1567-1569.
  15. Evangelou P, Tzotzas T, Christou G, Elisaf MS, Kiortsis DN: Does the presence of metabolic syndome influence weight loss in obese and overweight women? Metab Syndr Relat Disord 2010;8:173-178.
  16. Kantartzis K, Machann J, Schick F, Rittig K, Machicao F, Fritsche A, Haring HU, Stefan N: Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia 2011;54:864-868.
  17. Sesti G, Folli F, Perego L, Hribal ML, Pontiroli AE: Effects of weight loss in metabolically healthy obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. PLoS One 2011;6:e17737.
  18. Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R: Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 2008;51:1752-1754.
  19. Agueda M, Lasa A, Simon E, Ares R, Larrarte E, Labayen I: Association of circulating visfatin concentrations with insulin resistance and low-grade inflammation after dietary energy restriction in Spanish obese non-diabetic women: role of body composition changes. Nutr Metab Cardiovasc Dis 2012;22:208-214.
  20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
  21. Janiszewski PM, Ross R: Effects of weight loss among metabolically healthy obese men and women. Diabetes Care 2010;33:1957-1959.
  22. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
  23. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C: The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.
  24. Labayen I, Forga L, Martinez JA: Nutrient oxidation and metabolic rate as affected by meals containing different proportions of carbohydrate and fat, in healthy young women. Eur J Nutr 1999;38:158-166.
  25. Grattagliano I, Lauterburg BH, Palasciano G, Portincasa P: 13C-breath tests for clinical investigation of liver mitochondrial function. Eur J Clin Invest 2010;40:843-850.
  26. Karelis AD, Rabasa-Lhoret R: Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. Diabetes Metab 2008;34:183-184.
  27. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR: The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008;168:1617-1624.
  28. Ortega FB, Lee DC, Katzmarzyk PT, Ruiz JR, Sui X, Church TS, Blair SN: The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J 2012, E-pub ahead of print.
  29. Marini MA, Succurro E, Frontoni S, Hribal ML, Andreozzi F, Lauro R, Perticone F, Sesti G: Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care 2007;30:2145-2147.
  30. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998;68:899-917.
  31. Management of obesity in adults: project for European primary care. Int J Obes Relat Metab Disord 2004;28(suppl 1):S226-S231.

    External Resources

  32. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH: The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88.
  33. Stefan N, Kantartzis K, Haring HU: Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-960.
  34. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM: Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005;54:3140-3147.
  35. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, Schick F, Haring H, Stumvoll M: Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 2005;37:246-251.
  36. Shin MJ, Hyun YJ, Kim OY, Kim JY, Jang Y, Lee JH: Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond) 2006;30:1529-1534.
  37. Messier V, Karelis AD, Robillard ME, Bellefeuille P, Brochu M, Lavoie JM, Rabasa-Lhoret R: Metabolically healthy but obese individuals: relationship with hepatic enzymes. Metabolism 2010;59:20-24.
  38. Nanri A, Mizoue T, Takahashi Y, Noda M, Inoue M, Tsugane S: Weight change and all-cause, cancer and cardiovascular disease mortality in Japanese men and women: the Japan Public Health Center-Based Prospective Study. Int J Obes (Lond) 2010;34:348-356.
  39. Rzehak P, Meisinger C, Woelke G, Brasche S, Strube G, Heinrich J: Weight change, weight cycling and mortality in the ERFORT Male Cohort Study. Eur J Epidemiol 2007;22:665-673.
  40. Perez Morales ME, Jimenez Cruz A, Bacardi Gascon M: The effect of weight loss on mortality: a systematic review from 2000 to 2009 (in Spanish). Nutr Hosp 2010;25:718-724.

    External Resources

  41. Heymsfield SB, Harp JB, Reitman ML, Beetsch JW, Schoeller DA, Erondu N, Pietrobelli A: Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective. Am J Clin Nutr 2007;85:346-354.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50